Calaminus G, Jürgens H, Schwamborn D, Janssen G, Göbel U
Universitäts-Kinderklinik Düsseldorf, Abteilung für Hämatologie und Onkologie.
Klin Padiatr. 1989 Jul-Aug;201(4):311-5. doi: 10.1055/s-2008-1026720.
The efficiency and toxicity of Carboplatin, a derivate of cisplatin in clinical use since 1981, was investigated in combination with VP16 in 11 children with recurrent or refractory tumors. 10 patients received therapy as outpatients without hydration. 160 mg/m2/day of Carboplatin were administered days 1 to 3, or days 1 to 5 as one hour infusion, combined with VP16 100 mg/m2/day, days 1 to 3, or days 1 to 5 as one hour infusion. One patient received Carboplatin, 600 mg/m2, as 24 hrs. continuous infusion in combination with VM26, 150 mg/m2/day as one hour infusion, 8 hours after Carboplatin. 9 of the treated children had measurable disease. 3 of 9 patients achieved a tumor response of more than 50% (partial remission). 5 of 9 children showed tumor response of less than 50% (stable disease). 1 out of 9 patients had progressive disease. 8 of 9 patients reported improvement or disappearance of clinical symptoms after the first course. All patients had severe myelosuppression with different times to recover. The WBC nadir was 14 days after Carboplatin/VP16. The nadir platelet counts occurred 21 days after therapy with fast recovery. Non-hematological side effects were minimal.
卡铂是顺铂的衍生物，自1981年起用于临床。我们对11例复发或难治性肿瘤患儿联合使用卡铂和依托泊苷（VP16）的疗效及毒性进行了研究。10例患者作为门诊患者接受治疗，未进行水化。卡铂按160mg/m²/天，于第1至3天或第1至5天静脉输注1小时，联合VP16 100mg/m²/天，于第1至3天或第1至5天静脉输注1小时。1例患者接受卡铂600mg/m²持续输注24小时，联合VM26 150mg/m²/天静脉输注1小时，在卡铂输注8小时后进行。9例接受治疗的患儿有可测量的病灶。9例患者中有3例获得了超过50%的肿瘤反应（部分缓解）。9例患儿中有5例肿瘤反应小于50%（病情稳定）。9例患者中有1例病情进展。9例患者中有8例在第一个疗程后报告临床症状有所改善或消失。所有患者均有严重的骨髓抑制，恢复时间各不相同。白细胞最低点出现在卡铂/VP16治疗后14天。血小板计数最低点出现在治疗后21天，恢复较快。非血液学副作用轻微。
